CAR T-Cell Therapy Does Not Cure Multiple Myeloma
CAR T-cell therapy is not curative for multiple myeloma—it produces deep remissions and extends survival in relapsed/refractory disease, but virtually all patients eventually relapse. 1, 2
Current Evidence on Outcomes
The most recent NCCN and EHA-EMN guidelines clearly establish that while CAR T-cell therapy achieves remarkable response rates, multiple myeloma remains incurable 1, 2. Here's what the evidence shows:
Response Rates vs. Cure
Ciltacabtagene autoleucel (cilta-cel):
- In CARTITUDE-4 (2025), after one prior line of therapy: 73.1% achieved complete response or better, with median PFS not yet reached at 15.9 months follow-up 1
- In CARTITUDE-1, heavily pretreated patients (median 6 prior lines): 82.5% achieved stringent CR, but 27-month PFS was only 54.9% and OS 70.4% 2
- Critical point: Despite these impressive initial responses, duration of response, PFS, and OS were all shorter in high-risk patients, and the majority eventually relapse 2
Idecabtagene vicleucel (ide-cel):
- In KarMMa-3 (expanded approval 2024), after 2-4 prior lines: median PFS was 13.8 months vs 4.4 months with standard therapy 2
- At 31 months follow-up, median OS was 41.4 months in the ide-cel arm 2
- These are improvements in survival, not cures—the disease progresses in essentially all patients over time
Why CAR T-Cell Therapy Isn't Curative
The evidence demonstrates several key limitations:
Inevitable relapse occurs: Even with 82.5% stringent CR rates, the 27-month PFS of 54.9% means nearly half of patients have progressed by that timepoint 2
High-risk features predict shorter responses: Patients with high-risk cytogenetics, high tumor burden, or extramedullary disease have significantly shorter DOR, PFS, and OS 2, 3
Post-CAR T relapse is common: Studies specifically examining salvage therapy after CAR T-cell failure show that subsequent treatments are needed, with bispecific T-cell engagers achieving ORRs of 64-79% in this setting 2
The disease biology remains: Multiple myeloma is characterized by clonal evolution and heterogeneity that allows escape from even the most effective therapies 4, 5
Clinical Implications
CAR T-cell therapy should be positioned as a highly effective disease-modifying treatment that produces deep remissions and extends survival, not as a cure 1, 2. The 2025 guidelines recommend:
- Cilta-cel after one prior line (if lenalidomide-refractory) or in later lines 1
- Ide-cel after 2+ prior lines or in later lines 2
- Both agents for triple-class refractory disease 2
Sequencing Considerations
Current evidence suggests CAR T-cells should be given before BCMA-targeted antibody-drug conjugates or bispecific T-cell engagers when possible, as subsequent BCMA-directed therapies may be less effective after CAR T-cell failure 2. However, GPRC5D-targeted therapies (like talquetamab) show promising activity post-CAR T, with ORRs of 79-82% 2, 3.
Common Pitfall to Avoid
Do not counsel patients that CAR T-cell therapy will cure their myeloma. While these therapies represent a major advance with unprecedented response rates and depth of remission (including high rates of MRD negativity at 78% 3), the disease remains fundamentally incurable. Set realistic expectations: CAR T-cell therapy can produce years of disease control and excellent quality of life, but ongoing monitoring and eventual additional therapy will be necessary for virtually all patients.
The goal is disease control and prolonged survival with good quality of life, not cure 6, 7, 4.